Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Industry Examines China R&D Strategy Amidst Financial Crisis

This article was originally published in PharmAsia News

Executive Summary

In the face of sliding profit margins and imminent drug patent expiry, multinational drug firms are seeking different avenues such as investing in or buying biotech firms to acquire new drugs. Sanofi-Aventis does not discount such possibilities but advocates collaboration as a better model to retain talent and technology. The company recently established a partnership with the Shanghai Institute for Biological Sciences (PharmAsia News Oct. 23, 2008) to cooperate with local academic institutes instead of setting up its own R&D center. According to Sanofi officials, the firm's R&D investment this year will be flat or even decrease slightly. (Click here for more - Chinese Language)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC067009

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel